Mokam Life Science Institute - Cha Vaccine Institute, AI-Based New Drug Candidate Discovery Agreement

[Asia Economy Reporter Lee Gwan-joo] Mokam Life Science Research Institute announced on the 21st that it has signed a 'Mutual Cooperation Agreement for AI-based New Drug Candidate Discovery' with Cha Vaccine Institute.

Through this agreement, both parties will cooperate to develop new drugs using various AI algorithms. They will conduct joint research for discovering and improving new drug substances using AI, exchange physical and human resources for preliminary consultations on new drug candidate development, and jointly file intellectual property rights and publish papers resulting from the joint research.

Mokam Research Institute analyzes relevant data through its proprietary AI algorithms to study mechanisms occurring in cells and signal transduction processes, while Cha Vaccine Institute provides research data secured based on its innovative immune enhancement platform.

Kim Seon, Director of Mokam Life Science Research Institute, said, "We aim to create a new paradigm for new vaccine development and AI-based drug development by combining Mokam Research Institute's research capabilities with Cha Vaccine Institute's latest manufacturing technology."

Yeom Jeong-seon, CEO of Cha Vaccine Institute, stated, "Since new drug development requires enormous costs and time, active efforts using AI to shorten this process are underway. We will actively promote additional new drug development by integrating Mokam Life Science Research Institute's AI technology with Cha Vaccine Institute's technology, which is developing premium vaccines based on its independently developed immune enhancement platform."

This content was produced with the assistance of AI translation services.